Hims & Hers $HIMS tumbles 15% on Q1 net loss and weak guidance

Hims & Hers ($HIMS) fell roughly 15% on May 12, 2026 after the telehealth platform reported a first-quarter net loss and issued forward guidance below consensus expectations, according to CNBC.

Hims & Hers built significant revenue growth around compounded versions of semaglutide and tirzepatide — GLP-1 receptor agonists used for weight loss. Compound pharmacies were permitted to produce their own formulations while the branded drugs (Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Mounjaro/Zepbound) were on the FDA's shortage list. Once the FDA removed semaglutide from that list, compound pharmacies lost their regulatory exemption, directly curtailing Hims & Hers' highest-margin product category.

The weak guidance signals that the transition away from compounded GLP-1 drugs is proving costly. Competing directly against branded manufacturers puts Hims at a structural disadvantage on pricing and distribution. Investors are focused less on the specific quarterly loss figure and more on the timeline and credibility of any alternative revenue pathway.

The company operates a multi-category telehealth platform covering hair loss, erectile dysfunction, women's health, and mental wellness. Growth in non-GLP-1 categories remains an open question as to whether it can absorb the compounded-drug headwind fast enough to satisfy near-term profitability expectations.

Key dates ahead: Q2 2026 earnings and any additional FDA guidance on compounded medications.

Not investment advice. Verify all figures with primary sources before acting.